Global Gaps in Heart‑Risk Tools and Care Between Rich and Poor Nations
New research shows that the equations used to predict heart disease, the way pregnancy‑related heart problems are tracked, and the treatment of sudden heart failure differ sharply in high‑income versus low‑ and middle‑income countries. These differences leave many people without accurate risk scores or optimal care.
Key takeaways
- Risk equations built in wealthy nations mis‑estimate heart‑disease danger for people with diabetes in poorer settings, especially because age affects risk differently [1].
- Complications during pregnancy, such as high blood pressure or gestational diabetes, signal long‑term heart risk, but current tools do not fully capture this, and follow‑up plans are still unclear [2].
- In 17 African nations, acute heart‑failure patients are younger, have shifting causes of illness, and face high death rates despite varied treatments, pointing to gaps in prevention and post‑hospital care [3].
Risk scores need local tweaking
A large cohort study compared cardiovascular‑disease (CVD) risk equations derived from high‑income countries with those built from data in non‑high‑income nations. The researchers focused on patients with diabetes, a group at especially high heart risk. When they applied a high‑income‑country equation to the non‑high‑income cohort, the model systematically mis‑predicted risk. The biggest error came from the age factor, which behaved differently across settings.
Updating the equation with local age coefficients and other predictor weights dramatically improved calibration—the match between predicted and observed events. In the Chinese‑derived model, the expected‑to‑observed ratio was 1.027 for men and 1.025 for women, indicating very close alignment [1]. The authors argue that simply recalibrating a foreign model is not enough; key predictor coefficients must be revised for each income setting.
Pregnancy complications as an early heart‑risk alarm
A Lancet review highlighted that pregnancy acts as a natural stress test for the cardiovascular system. Conditions such as hypertensive disorders of pregnancy (high blood pressure that develops during pregnancy), gestational diabetes (high blood sugar that appears only during pregnancy), and preterm birth (delivery before 37 weeks) can reveal hidden susceptibility to later heart disease.
The authors propose that a woman’s history of adverse pregnancy outcomes (APOs) be woven into long‑term heart‑risk assessments. However, they note major knowledge gaps. Current risk‑stratification tools do not fully incorporate APOs, and there are no dedicated prevention trials that test interventions specifically for women with such histories. Moreover, the best way to follow these women after pregnancy—how often they should be seen, which tests to order, or which lifestyle changes to emphasize—remains uncertain [2].
Acute heart failure looks different in Africa
The THESUS‑HF II study gathered data from hospitals in 17 African countries to describe who gets acute heart failure, how they are treated, and what happens after discharge. The cohort was relatively young compared with typical Western heart‑failure populations. The causes of heart failure appear to be shifting, though the authors caution that differences in diagnostic capacity may partly explain the change.
Despite varied treatment patterns, the 180‑day mortality remained high. The study found that short‑term outcomes were not driven by demographic factors (age, sex), underlying causes, or echocardiographic findings (heart‑ultrasound results). This suggests that broader system issues—such as limited access to cardiac care, inconsistent use of guideline‑directed medicines, and weak post‑hospital follow‑up—play a major role in the poor prognosis [3].
Why the divide matters
Together, these three bodies of work illustrate a common theme: tools and care pathways developed in high‑income environments often do not translate directly to low‑ and middle‑income settings. The age‑specific risk mis‑fit in diabetes patients shows that a single global equation can misclassify many individuals, potentially leading to under‑ or over‑treatment.
For women, ignoring pregnancy‑related signals may miss an early window to intervene, especially in regions where maternal health services are already stretched. The lack of APO‑specific prevention research means that policies cannot be tailored to the unique risk patterns seen in different income groups.
In acute heart failure, the young age of patients in Africa contradicts the typical picture of older, chronic heart‑failure sufferers in wealthier nations. Yet the high death rate persists even when treatments appear similar, hinting that factors beyond the bedside—such as drug availability, follow‑up infrastructure, and patient education—are decisive.
What remains unknown
All three studies call for more data. The diabetes‑risk work suggests that updating predictor coefficients improves accuracy, but larger validation efforts across diverse low‑ and middle‑income populations are needed. The pregnancy‑risk review stresses the need for trials that test specific prevention strategies for women with APOs, and for real‑world studies that compare different follow‑up models. The African heart‑failure research points to the necessity of longitudinal studies that track patients beyond six months and examine the impact of health‑system improvements.
Looking ahead
The evidence underscores that a one‑size‑fits‑all approach to cardiovascular risk and treatment is insufficient. Tailoring risk equations to local demographics, integrating women’s pregnancy histories into heart‑health checks, and strengthening acute‑care pathways in resource‑limited settings could narrow the outcome gap. Researchers, policymakers, and health‑system leaders must collaborate to build region‑specific tools and to test interventions that address the unique challenges of each income setting. Only then can the global burden of heart disease be reduced equitably.
